Trial · NCT03010176
Participant flow30
How many started, completed or left each group, period by period.
1 to 20 of 30
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Part 1 Arm 1: Ulevostinag (Cut/Subcut Lesions) | 32 | |
| Overall Study | STARTED | Part 1 Arm 2: Ulevostinag+Pembro (Cut/Subcut Lesions) | 52 | |
| Overall Study | STARTED | Part 1 Arm 3: Ulevostinag+Pembro (Visceral Lesions) | 26 | |
| Overall Study | STARTED | Part 2 Cohort A: HNSCC Anti-PD-1/PD-L1 Refractory | 21 | |
| Overall Study | STARTED | Part 2 Cohort B: Anti-PD-1/PD-L1 TrT-Naïve or Refractory TNBC | 25 | |
| Overall Study | STARTED | Part 2 Cohort C: Anti-PD-1/PD-L1 TrT-Naïve Solid Tumors-Liver | 0 | |
| Overall Study | Treated | Part 1 Arm 1: Ulevostinag (Cut/Subcut Lesions) | 32 | |
| Overall Study | Treated | Part 1 Arm 2: Ulevostinag+Pembro (Cut/Subcut Lesions) | 52 | |
| Overall Study | Treated | Part 1 Arm 3: Ulevostinag+Pembro (Visceral Lesions) | 26 | |
| Overall Study | Treated | Part 2 Cohort A: HNSCC Anti-PD-1/PD-L1 Refractory | 21 | |
| Overall Study | Treated | Part 2 Cohort B: Anti-PD-1/PD-L1 TrT-Naïve or Refractory TNBC | 25 | |
| Overall Study | Treated | Part 2 Cohort C: Anti-PD-1/PD-L1 TrT-Naïve Solid Tumors-Liver | 0 | |
| Overall Study | Switched From Part 1 Arm 1 to Part 1 Arm 2 | Part 1 Arm 1: Ulevostinag (Cut/Subcut Lesions) | 14 | |
| Overall Study | Switched From Part 1 Arm 1 to Part 1 Arm 2 | Part 1 Arm 2: Ulevostinag+Pembro (Cut/Subcut Lesions) | 0 | |
| Overall Study | Switched From Part 1 Arm 1 to Part 1 Arm 2 | Part 1 Arm 3: Ulevostinag+Pembro (Visceral Lesions) | 0 | |
| Overall Study | Switched From Part 1 Arm 1 to Part 1 Arm 2 | Part 2 Cohort A: HNSCC Anti-PD-1/PD-L1 Refractory | 0 | |
| Overall Study | Switched From Part 1 Arm 1 to Part 1 Arm 2 | Part 2 Cohort B: Anti-PD-1/PD-L1 TrT-Naïve or Refractory TNBC | 0 | |
| Overall Study | Switched From Part 1 Arm 1 to Part 1 Arm 2 | Part 2 Cohort C: Anti-PD-1/PD-L1 TrT-Naïve Solid Tumors-Liver | 0 | |
| Overall Study | COMPLETED | Part 1 Arm 1: Ulevostinag (Cut/Subcut Lesions) | 0 | |
| Overall Study | COMPLETED | Part 1 Arm 2: Ulevostinag+Pembro (Cut/Subcut Lesions) | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03010176/flow